☰

David P. Lane - Publications

Affiliations: 
Institute of Molecular and Cell Biology (A-STAR), Singapore, Singapore 
Tree Info Similar researchers PubMed Report error

400 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Philippe GJ, Huang YH, Mittermeier A, Brown CJ, Kaas Q, Ramlan SR, Wang CK, Lane D, Loewer A, Troeira Henriques S, Craik DJ. Delivery to, and Reactivation of, the p53 Pathway in Cancer Cells Using a Grafted Cyclotide Conjugated with a Cell-Penetrating Peptide. Journal of Medicinal Chemistry. PMID 38174919 DOI: 10.1021/acs.jmedchem.3c01682  0.3
2023 Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Fernández AP, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, ... ... Lane DP, et al. Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nature Communications. 14: 5019. PMID 37596290 DOI: 10.1038/s41467-023-40764-2  0.325
2023 Lerma Clavero A, Boqvist PL, Ingelshed K, Bosdotter C, Sedimbi S, Jiang L, Wermeling F, Vojtesek B, Lane DP, Kannan P. MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia. Scientific Reports. 13: 4583. PMID 36941277 DOI: 10.1038/s41598-023-31484-0  0.323
2023 Lane DP, Verma CS. Covalent Rescue of Mutant p53. Cancer Discovery. 13: 14-16. PMID 36620883 DOI: 10.1158/2159-8290.CD-22-1212  0.386
2022 Ingelshed K, Spiegelberg D, Kannan P, Påvénius L, Hacheney J, Jiang L, Eisinger S, Lianoudaki D, Lama D, Castillo F, Bosdotter C, Kretzschmar WW, Al-Radi O, Fritz N, Villablanca EJ, ... ... Lane DP, et al. The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth and Potentiates Radiotherapy. Cancer Research Communications. 2: 1075-1088. PMID 36922937 DOI: 10.1158/2767-9764.CRC-22-0053  0.378
2022 Kaldmäe M, Vosselman T, Zhong X, Lama D, Chen G, Saluri M, Kronqvist N, Siau JW, Ng AS, Ghadessy FJ, Sabatier P, Vojtesek B, Sarr M, Sahin C, Österlund N, ... ... Lane DP, et al. A "spindle and thread" mechanism unblocks p53 translation by modulating N-terminal disorder. Structure (London, England : 1993). PMID 35290795 DOI: 10.1016/j.str.2022.02.013  0.3
2022 Wang YH, Ho TLF, Hariharan A, Goh HC, Wong YL, Verkaik NS, Lee MY, Tam WL, van Gent DC, Venkitaraman AR, Sheetz MP, Lane DP. Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity. Proceedings of the National Academy of Sciences of the United States of America. 119: e2113233119. PMID 35235448 DOI: 10.1073/pnas.2113233119  0.35
2021 Jiang L, Ingelshed K, Shen Y, Boddul SV, Iyer VS, Kasza Z, Sedimbi S, Lane DP, Wermeling F. CRISPR/Cas9-induced DNA damage enriches for mutations in a p53-linked interactome: implications for CRISPR-based therapies. Cancer Research. PMID 34750099 DOI: 10.1158/0008-5472.CAN-21-1692  0.386
2021 Bhatta B, Luz I, Krueger C, Teo FX, Lane DP, Sabapathy K, Cooks T. Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment. Cancers. 13. PMID 34203762 DOI: 10.3390/cancers13122985  0.335
2020 Ladds MJGW, Popova G, Pastor-Fernández A, Kannan S, van Leeuwen IMM, Håkansson M, Walse B, Tholander F, Bhatia R, Verma CS, Lane DP, Laín S. Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. The Journal of Biological Chemistry. 295: 17935-17949. PMID 33453808 DOI: 10.1074/jbc.RA119.012056  0.307
2020 Ng S, Juang YC, Chandramohan A, Kaan HYK, Sadruddin A, Yuen TY, Ferrer-Gago FJ, Lee XC, Liew X, Johannes CW, Brown CJ, Kannan S, Aronica PG, Berglund NA, Verma CS, ... ... Lane DP, et al. De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits. Acs Medicinal Chemistry Letters. 11: 1993-2001. PMID 33062184 DOI: 10.1021/Acsmedchemlett.0C00022  0.339
2020 Ladds MJGW, Popova G, Pastor-Fernández A, Kannan S, van Leeuwen IMM, Håkansson M, Walse B, Tholander F, Bhatia R, Verma CS, Lane DP, Laín S. Exploitation of DHODH and p53 activation as therapeutic targets - a case study in polypharmacology. The Journal of Biological Chemistry. PMID 32900849 DOI: 10.1074/Jbc.Ra119.012056  0.421
2020 Kannan S, Aronica PGA, Ng S, Gek Lian DT, Frosi Y, Chee S, Shimin J, Yuen TY, Sadruddin A, Kaan HYK, Chandramohan A, Wong JH, Tan YS, Chang ZW, Ferrer-Gago FJ, ... ... Lane DP, et al. Macrocyclization of an all-d linear α-helical peptide imparts cellular permeability. Chemical Science. 11: 5577-5591. PMID 32874502 DOI: 10.1039/C9Sc06383H  0.32
2020 Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, Vinel C, Almstedt E, Elgendy R, Elfineh L, Gallant C, Lundsten S, Ferrer Gago FJ, Hakkarainen A, Sipilä P, ... ... Lane DP, et al. A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. Cell Reports. 32: 107897. PMID 32668248 DOI: 10.1016/J.Celrep.2020.107897  0.324
2020 Kong LR, Ong RW, Tan TZ, Mohamed Salleh NAB, Thangavelu M, Chan JV, Koh LYJ, Periyasamy G, Lau JA, Le TBU, Wang L, Lee M, Kannan S, Verma CS, Lim CM, ... ... Lane DP, et al. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nature Communications. 11: 2086. PMID 32350249 DOI: 10.1038/S41467-020-15608-Y  0.458
2020 Lundsten S, Hernández VA, Gedda L, Sarén T, Brown CJ, Lane DP, Edwards K, Nestor M. Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks. Nanomaterials (Basel, Switzerland). 10. PMID 32325827 DOI: 10.3390/Nano10040783  0.353
2020 Mortensen ACL, Morin E, Brown CJ, Lane DP, Nestor M. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2. Ejnmmi Research. 10: 38. PMID 32300907 DOI: 10.1186/S13550-020-0613-7  0.339
2020 Popova G, Ladds MJGW, Johansson L, Saleh A, Larsson J, Sandberg L, Sahlberg SH, Qian W, Gullberg H, Garg N, Gustavsson AL, Haraldsson M, Lane DP, Yngve U, Lain S. Optimization of tetrahydroindazoles as inhibitors of human dihydroorotate dehydrogenase and evaluation of their activity and in vitro metabolic stability. Journal of Medicinal Chemistry. PMID 32212728 DOI: 10.1021/Acs.Jmedchem.9B01658  0.351
2020 Lim S, Khoo R, Peh KM, Teo J, Chang SC, Ng S, Beilhartz GL, Melnyk RA, Johannes CW, Brown CJ, Lane DP, Henry B, Partridge AW. bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA). Proceedings of the National Academy of Sciences of the United States of America. PMID 32123106 DOI: 10.1073/Pnas.1920251117  0.335
2020 Ingelshed K, Lianoudaki D, Lama D, Sohn S, Fritz N, Jiang L, Wermeling F, Karlsson M, Lane DP, Sedimbi SK. Abstract A79: Inhibition of p53-MDM2 protein interaction reduces tumor growth in a mouse melanoma model Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-A79  0.445
2019 Sabapathy K, Lane DP. Corrigendum to 'Understanding p53 functions through p53 antibodies'. Journal of Molecular Cell Biology. 11: 1105. PMID 31881082 DOI: 10.1093/Jmcb/Mjz110  0.449
2019 Ho T, Tan BX, Lane D. How the Other Half Lives: What p53 Does When It Is Not Being a Transcription Factor. International Journal of Molecular Sciences. 21. PMID 31861395 DOI: 10.3390/Ijms21010013  0.45
2019 Kannan S, Partridge AW, Lane DP, Verma CS. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors. International Journal of Molecular Sciences. 20. PMID 31795143 DOI: 10.3390/Ijms20235996  0.52
2019 Frosi Y, Inoue K, Ramlan SR, Lane DP, Watanabe T, Brown CJ. Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci. Scientific Reports. 9: 17933. PMID 31784573 DOI: 10.1038/S41598-019-54123-Z  0.482
2019 Mortensen ACL, Spiegelberg D, Brown CJ, Lane DP, Nestor M. The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells. Frontiers in Oncology. 9: 923. PMID 31616635 DOI: 10.3389/Fonc.2019.00923  0.445
2019 Koh XY, Koh XH, Hwang LA, Ferrer FJ, Rahmat SAB, Lama D, Lane DP. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase. Oncogene. PMID 31417186 DOI: 10.1038/S41388-019-0946-8  0.328
2019 Xue Y, San Luis B, Lane DP. Intratumour heterogeneity of p53 expression; causes and consequences. The Journal of Pathology. PMID 31322742 DOI: 10.1002/Path.5328  0.475
2019 Yuen TY, Brown CJ, Xue Y, Tan YS, Ferrer Gago FJ, Lee XE, Neo JY, Thean D, Kaan HYK, Partridge AW, Verma CS, Lane DP, Johannes CW. Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles. Chemical Science. 10: 6457-6466. PMID 31316744 DOI: 10.1039/C9Sc01456J  0.403
2019 Partridge AW, Kaan HYK, Juang YC, Sadruddin A, Lim S, Brown CJ, Ng S, Thean D, Ferrer F, Johannes C, Yuen TY, Kannan S, Aronica P, Tan YS, Pradhan MR, ... ... Lane DP, et al. Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties. Molecules (Basel, Switzerland). 24. PMID 31226791 DOI: 10.3390/Molecules24122292  0.303
2019 Lane DP, Verma CS. p53: updates on mechanisms, biology and therapy (II). Journal of Molecular Cell Biology. 11: 265-266. PMID 31222348 DOI: 10.1093/Jmcb/Mjz018  0.339
2019 Xue Y, Barker N, Hoon S, He P, Thakur T, Abdeen SR, Maruthappan P, Ghadessy FJ, Lane DP. Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo. Cancer Research. PMID 31138526 DOI: 10.1158/0008-5472.Can-18-3744  0.496
2019 Sabapathy K, Lane DP. Understanding p53 functions through p53 antibodies. Journal of Molecular Cell Biology. PMID 30907951 DOI: 10.1093/Jmcb/Mjz010  0.507
2019 Lama D, Liberatore AM, Frosi Y, Nakhle J, Tsomaia N, Bashir T, Lane DP, Brown CJ, Verma CS, Auvin S. Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein. Chemical Science. 10: 2489-2500. PMID 30881679 DOI: 10.1039/C8Sc03759K  0.329
2019 Pradhan MR, Siau JW, Kannan S, Nguyen MN, Ouaray Z, Kwoh CK, Lane DP, Ghadessy F, Verma CS. Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket. Nucleic Acids Research. PMID 30649466 DOI: 10.1093/Nar/Gky1314  0.36
2019 Johansson P, Almstedt E, Doroszko M, Kundu S, Vinel C, Lane D, Nestor M, Marino S, Krona C, Nelander S. COMP-05. A DRUG ASSOCIATION MAP OF GLIOBLASTOMA INFORMS PRECISION TARGETING OF p53-DEPENDENT METABOLIC STATES Neuro-Oncology. 21: vi62-vi62. DOI: 10.1093/Neuonc/Noz175.248  0.36
2019 Zheng XT, Goh WL, Yeow P, Lane DP, Ghadessy FJ, Tan YN. Ultrasensitive dynamic light scattering based nanobiosensor for rapid anticancer drug screening Sensors and Actuators B: Chemical. 279: 79-86. DOI: 10.1016/J.Snb.2018.09.088  0.383
2018 Lau SY, Siau JW, Sobota RM, Wang CI, Zhong P, Lane DP, Ghadessy FJ. Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function. Protein Engineering, Design & Selection : Peds. PMID 30169723 DOI: 10.1093/Protein/Gzy018  0.389
2018 Spiegelberg D, Mortensen AC, Lundsten S, Brown CJ, Lane DP, Nestor M. The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors. Cancer Research. PMID 30026328 DOI: 10.1158/0008-5472.Can-18-0440  0.455
2018 Assah E, Goh W, Zheng XT, Lim TX, Li J, Lane D, Ghadessy F, Tan YN. Rapid colorimetric detection of p53 protein function using DNA-gold nanoconjugates with applications for drug discovery and cancer diagnostics. Colloids and Surfaces. B, Biointerfaces. 169: 214-221. PMID 29778960 DOI: 10.1016/J.Colsurfb.2018.05.007  0.499
2018 Ladds MJGW, Pastor-Fernández A, Popova G, van Leeuwen IMM, Eng KE, Drummond CJ, Johansson L, Svensson R, Westwood NJ, McCarthy AR, Tholander F, Popa M, Lane DP, McCormack E, McInerney GM, et al. Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. Plos One. 13: e0195956. PMID 29684045 DOI: 10.1371/Journal.Pone.0195956  0.369
2018 Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, ... ... Lane DP, et al. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nature Communications. 9: 1107. PMID 29549331 DOI: 10.1038/S41467-018-03441-3  0.468
2018 von Muhlinen N, Horikawa I, Alam F, Isogaya K, Lissa D, Vojtesek B, Lane DP, Harris CC. p53 isoforms regulate premature aging in human cells. Oncogene. PMID 29429991 DOI: 10.1038/S41388-017-0101-3  0.438
2018 Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP, Sabapathy K. Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine. Cell Reports. 22: 299-312. PMID 29298430 DOI: 10.1016/J.Celrep.2017.11.112  0.415
2017 Chan JV, Ping Koh DX, Liu Y, Joseph TL, Lane DP, Verma CS, Tan YS. Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53. Oncotarget. 8: 112825-112840. PMID 29348869 DOI: 10.18632/Oncotarget.22829  0.494
2017 Chee SMQ, Wongsantichon J, Siau J, Thean D, Ferrer F, Robinson RC, Lane DP, Brown CJ, Ghadessy FJ. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids. Plos One. 12: e0189379. PMID 29228061 DOI: 10.1371/Journal.Pone.0189379  0.378
2017 Yadahalli S, Li J, Lane DP, Gosavi S, Verma CS. Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations. Scientific Reports. 7: 15600. PMID 29142290 DOI: 10.1038/S41598-017-15930-4  0.361
2017 Muller P, Chan JM, Simoncik O, Fojta M, Lane DP, Hupp T, Vojtesek B. Evidence for allosteric effects on p53 oligomerization induced by phosphorylation. Protein Science : a Publication of the Protein Society. PMID 29124793 DOI: 10.1002/Pro.3344  0.659
2017 Wong JH, Alfatah M, Sin MF, Sim HM, Verma CS, Lane DP, Arumugam P. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53. Bmc Biology. 15: 108. PMID 29121928 DOI: 10.1186/S12915-017-0446-7  0.371
2017 Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nature Reviews. Clinical Oncology. PMID 28948977 DOI: 10.1038/Nrclinonc.2017.151  0.445
2017 Zheng S, Koh XY, Goh HC, Rahmat SAB, Hwang LA, Lane DP. Inhibiting p53 acetylation reduces cancer chemotoxicity. Cancer Research. PMID 28655792 DOI: 10.1158/0008-5472.Can-17-0424  0.479
2017 Thean D, Ebo JS, Luxton T, Lee XC, Yuen TY, Ferrer FJ, Johannes CW, Lane DP, Brown CJ. Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery. Scientific Reports. 7: 1763. PMID 28496125 DOI: 10.1038/S41598-017-01712-5  0.369
2017 Cheok CF, Lane DP. Exploiting the p53 Pathway for Therapy. Cold Spring Harbor Perspectives in Medicine. PMID 28193768 DOI: 10.1101/Cshperspect.A026310  0.416
2017 Tan BX, Liew HP, Chua JS, Ghadessy FJ, Tan YS, Lane DP, Coffill CR. Anatomy of Mdm2 and Mdm4 in evolution. Journal of Molecular Cell Biology. PMID 28077607 DOI: 10.1093/Jmcb/Mjx002  0.467
2016 Xue Y, Raharja A, Sim W, Wong ES, Rahmat SA, Lane DP. The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage. Oncogene. PMID 27869164 DOI: 10.1038/Onc.2016.374  0.478
2016 Siau JW, Coffill CR, Zhang WV, Tan YS, Hundt J, Lane D, Verma C, Ghadessy F. Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens. Scientific Reports. 6: 33972. PMID 27678309 DOI: 10.1038/Srep33972  0.49
2016 Tan YS, Lane DP, Verma CS. Stapled peptide design: principles and roles of computation. Drug Discovery Today. PMID 27326912 DOI: 10.1016/J.Drudis.2016.06.012  0.304
2016 Ouaray Z, ElSawy KM, Lane DP, Essex JW, Verma C. Reactivation of mutant p53: Constraints on mechanism highlighted by principal component analysis of the DNA binding domain. Proteins. PMID 27317883 DOI: 10.1002/Prot.25089  0.434
2016 Turnquist C, Horikawa I, Foran E, Major EO, Vojtesek B, Lane DP, Lu X, Harris BT, Harris CC. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death and Differentiation. PMID 27104929 DOI: 10.1038/Cdd.2016.37  0.311
2016 Lane D. p53: out of Africa. Genes & Development. 30: 876-7. PMID 27083994 DOI: 10.1101/Gad.281733.116  0.423
2016 Wei SJ, Chee S, Yurlova L, Lane D, Verma C, Brown C, Ghadessy F. Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides. Oncotarget. PMID 27057630 DOI: 10.18632/Oncotarget.8572  0.399
2016 Kannan S, Lane DP, Verma CS. Long range recognition and selection in IDPs: the interactions of the C-terminus of p53. Scientific Reports. 6: 23750. PMID 27030593 DOI: 10.1038/Srep23750  0.367
2016 Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans. Genes & Development. PMID 26798135 DOI: 10.1101/Gad.274118.115  0.481
2016 Pradhan MR, Ouray Z, Kannan S, Lane DP, Verma CS. Dynamics of Aggregating Mutants of the P53 DNA Binding Domain Reveal A Novel “Druggable” Pocket Biophysical Journal. 110: 55a. DOI: 10.1016/J.Bpj.2015.11.361  0.39
2015 Geng J, Goh WL, Zhang C, Lane DP, Liu B, Ghadessy F, Tan YN. A highly sensitive fluorescent light-up probe for real-time detection of the endogenous protein target and its antagonism in live cells. Journal of Materials Chemistry. B. 3: 5933-5937. PMID 32262648 DOI: 10.1039/C5Tb00819K  0.36
2015 ElSawy KM, Lane DP, Verma CS, Caves LS. Recognition Dynamics of p53 and MDM2: Implications for Peptide Design. The Journal of Physical Chemistry. B. PMID 26701330 DOI: 10.1021/Acs.Jpcb.5B11162  0.392
2015 Pradhan MR, Pal A, Hu Z, Kannan S, Kwoh CK, Lane DP, Verma CS. Wetting of non-conserved residue-backbones: A feature indicative of aggregation associated regions of proteins. Proteins. PMID 26677132 DOI: 10.1002/Prot.24976  0.313
2015 Ng JW, Lama D, Lukman S, Lane DP, Verma CS, Sim AY. R248Q mutation - Beyond p53-DNA binding. Proteins. PMID 26442703 DOI: 10.1002/Prot.24940  0.407
2015 Lama D, Brown CJ, Lane DP, Verma CS. Gating by Tryptophan 73 Exposes a Cryptic Pocket at the Protein-Binding Interface of the Oncogenic eIF4E Protein. Biochemistry. PMID 26427906 DOI: 10.1021/Acs.Biochem.5B00812  0.354
2015 Goh AM, Xue Y, Leushacke M, Li L, Wong JS, Chiam PC, Rahmat SA, Mann MB, Mann KM, Barker N, Lozano G, Terzian T, Lane DP. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 6: 17968-80. PMID 26255629 DOI: 10.18632/Oncotarget.4956  0.503
2015 Voon YL, Ahmad M, Wong PF, Husaini R, Ng WT, Leong CO, Lane DP, Khoo AS. Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity. Oncology Reports. 34: 1692-700. PMID 26252575 DOI: 10.3892/Or.2015.4177  0.485
2015 Tan BX, Brown CJ, Ferrer FJ, Yuen TY, Quah ST, Chan BH, Jansson AE, Teo HL, Nordlund P, Lane DP. Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays. Scientific Reports. 5: 12116. PMID 26159518 DOI: 10.1038/Srep12116  0.357
2015 Lama D, Quah ST, Brown CJ, Lane DP, Verma CS. 159 Stapled-peptides targeting the protein-binding interface of eukaryotic Translation Initiation Factor 4E (eIF4E) protein. Journal of Biomolecular Structure & Dynamics. 33: 102-3. PMID 26103369 DOI: 10.1080/07391102.2015.1032796  0.334
2015 Chua JS, Liew HP, Guo L, Lane DP. Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish. Oncogene. PMID 25746004 DOI: 10.1038/Onc.2015.57  0.452
2015 Gong L, Gong H, Pan X, Chang C, Ou Z, Ye S, Yin L, Yang L, Tao T, Zhang Z, Liu C, Lane DP, Peng J, Chen J. p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. Cell Research. 25: 351-69. PMID 25698579 DOI: 10.1038/Cr.2015.22  0.386
2015 ElSawy KM, Sim A, Lane DP, Verma CS, Caves LS. A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2. Cell Cycle (Georgetown, Tex.). 14: 179-88. PMID 25584963 DOI: 10.4161/15384101.2014.989043  0.46
2015 Li L, Ng DS, Mah WC, Almeida FF, Rahmat SA, Rao VK, Leow SC, Laudisi F, Peh MT, Goh AM, Lim JS, Wright GD, Mortellaro A, Taneja R, Ginhoux F, ... ... Lane DP, et al. A unique role for p53 in the regulation of M2 macrophage polarization. Cell Death and Differentiation. 22: 1081-93. PMID 25526089 DOI: 10.1038/Cdd.2014.212  0.396
2015 Yurlova L, Buchfellner A, Ruf B, Jo SGM, Bourdon J, Ghadessy FJ, Brown CJ, Lane DP, Romer T. Abstract 1231: Live cell and in vitro analysis of p53 interactions Cancer Research. 75: 1231-1231. DOI: 10.1158/1538-7445.Am2015-1231  0.523
2014 Sim AY, Joseph T, Lane DP, Verma C. Mechanism of Stapled Peptide Binding to MDM2: Possible Consequences for Peptide Design. Journal of Chemical Theory and Computation. 10: 1753-61. PMID 26580383 DOI: 10.1021/Ct4009238  0.442
2014 Horikawa I, Fujita K, Jenkins LM, Hiyoshi Y, Mondal AM, Vojtesek B, Lane DP, Appella E, Harris CC. Autophagic degradation of the inhibitory p53 isoform Δ133p53α as a regulatory mechanism for p53-mediated senescence. Nature Communications. 5: 4706. PMID 25144556 DOI: 10.1038/Ncomms5706  0.48
2014 Chee SM, Wongsantichon J, Soo Tng Q, Robinson R, Joseph TL, Verma C, Lane DP, Brown CJ, Ghadessy FJ. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. Plos One. 9: e104914. PMID 25115702 DOI: 10.1371/Journal.Pone.0104914  0.384
2014 Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death and Differentiation. 21: 1377-87. PMID 24926616 DOI: 10.1038/Cdd.2014.73  0.421
2014 Huang YF, Wee S, Gunaratne J, Lane DP, Bulavin DV. Isg15 controls p53 stability and functions. Cell Cycle (Georgetown, Tex.). 13: 2200-10. PMID 24844324 DOI: 10.4161/Cc.29209  0.504
2014 Lau YH, de Andrade P, Sköld N, McKenzie GJ, Venkitaraman AR, Verma C, Lane DP, Spring DR. Investigating peptide sequence variations for 'double-click' stapled p53 peptides. Organic & Biomolecular Chemistry. 12: 4074-7. PMID 24817343 DOI: 10.1039/C4Ob00742E  0.396
2014 Tan BX, Khoo KH, Lim TM, Lane DP. High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia. Oncotarget. 5: 933-43. PMID 24659749 DOI: 10.18632/Oncotarget.1559  0.504
2014 Khoo KH, Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature Reviews. Drug Discovery. 13: 217-36. PMID 24577402 DOI: 10.1038/Nrd4236  0.446
2014 Yurlova L, Derks M, Buchfellner A, Hickson I, Janssen M, Morrison D, Stansfield I, Brown CJ, Ghadessy FJ, Lane DP, Rothbauer U, Zolghadr K, Krausz E. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4. Journal of Biomolecular Screening. 19: 516-25. PMID 24476585 DOI: 10.1177/1087057113518067  0.381
2014 Yurlova L, Brown CJ, Derks M, Ghadessy FJ, Hickson I, Lane DP, Krausz E, Zolghadr K. Abstract 5386: Disrupting p53:Mdm2 and p53:Mdm4 - Comparative cell-based assays for drug screening Cancer Research. 74: 5386-5386. DOI: 10.1158/1538-7445.Am2014-5386  0.485
2014 Lau YH, De Andrade P, Quah ST, Rossmann M, Laraia L, Sköld N, Sum TJ, Rowling PJE, Joseph TL, Verma C, Hyvönen M, Itzhaki LS, Venkitaraman AR, Brown CJ, Lane DP, et al. Functionalised staple linkages for modulating the cellular activity of stapled peptides Chemical Science. 5: 1804-1809. DOI: 10.1039/C4Sc00045E  0.337
2013 Lama D, Quah ST, Verma CS, Lakshminarayanan R, Beuerman RW, Lane DP, Brown CJ. Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces. Scientific Reports. 3: 3451. PMID 24336354 DOI: 10.1038/Srep03451  0.334
2013 Lukman S, Lane DP, Verma CS. Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics. Plos One. 8: e80221. PMID 24324553 DOI: 10.1371/Journal.Pone.0080221  0.387
2013 Wei SJ, Joseph T, Chee S, Li L, Yurlova L, Zolghadr K, Brown C, Lane D, Verma C, Ghadessy F. Inhibition of nutlin-resistant HDM2 mutants by stapled peptides. Plos One. 8: e81068. PMID 24278380 DOI: 10.1371/Journal.Pone.0081068  0.44
2013 ElSawy KM, Verma CS, Lane DP, Caves LS. On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein. Cell Cycle (Georgetown, Tex.). 12: 3727-35. PMID 24270847 DOI: 10.4161/Cc.27273  0.34
2013 Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, Mazur SJ, Appella E, Vojtesek B, Blasco MA, Lane DP, Harris CC. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. The Journal of Clinical Investigation. 123: 5247-57. PMID 24231352 DOI: 10.1172/Jci70355  0.401
2013 Wong JS, Warbrick E, Vojtesk B, Hill J, Lane DP. Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth. Oncotarget. 4: 1019-36. PMID 23859937 DOI: 10.18632/Oncotarget.1075  0.309
2013 Wei SJ, Joseph T, Sim AY, Yurlova L, Zolghadr K, Lane D, Verma C, Ghadessy F. In vitro selection of mutant HDM2 resistant to Nutlin inhibition. Plos One. 8: e62564. PMID 23653682 DOI: 10.1371/Journal.Pone.0062564  0.459
2013 Nirantar SR, Yeo KS, Chee S, Lane DP, Ghadessy FJ. A generic scaffold for conversion of peptide ligands into homogenous biosensors. Biosensors & Bioelectronics. 47: 421-8. PMID 23612064 DOI: 10.1016/J.Bios.2013.03.049  0.315
2013 Tao T, Shi H, Guan Y, Huang D, Chen Y, Lane DP, Chen J, Peng J. Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. Cell Research. 23: 620-34. PMID 23357851 DOI: 10.1038/Cr.2013.16  0.504
2013 ElSawy KM, Verma CS, Joseph TL, Lane DP, Twarock R, Caves LS. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell Cycle (Georgetown, Tex.). 12: 394-404. PMID 23324352 DOI: 10.4161/Cc.23511  0.462
2013 Chee JL, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, Phua YT, Gabra H, Lim TM. Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle (Georgetown, Tex.). 12: 278-88. PMID 23255126 DOI: 10.4161/Cc.23054  0.501
2013 Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, Choong ML, Lee MA, Yurlova L, Zolghadr K, Joseph TL, Verma CS, Lane DP. Stapled peptides with improved potency and specificity that activate p53. Acs Chemical Biology. 8: 506-12. PMID 23214419 DOI: 10.1021/Cb3005148  0.444
2013 Marcel V, Khoury MP, Fernandes K, Diot A, Lane DP, Bourdon JC. Detecting p53 isoforms at protein level. Methods in Molecular Biology (Clifton, N.J.). 962: 15-29. PMID 23150434 DOI: 10.1007/978-1-62703-236-0_2  0.501
2013 Khoury MP, Marcel V, Fernandes K, Diot A, Lane DP, Bourdon JC. Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. Methods in Molecular Biology (Clifton, N.J.). 962: 1-14. PMID 23150433 DOI: 10.1007/978-1-62703-236-0_1  0.379
2013 Guo L, Liew HP, Camus S, Goh AM, Chee LL, Lunny DP, Lane EB, Lane DP. Ionizing radiation induces a dramatic persistence of p53 protein accumulation and DNA damage signaling in mutant p53 zebrafish. Oncogene. 32: 4009-16. PMID 23069659 DOI: 10.1038/Onc.2012.409  0.458
2013 Nicol SM, Bray SE, Black HD, Lorimore SA, Wright EG, Lane DP, Meek DW, Coates PJ, Fuller-Pace FV. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage. Oncogene. 32: 3461-9. PMID 22986526 DOI: 10.1038/Onc.2012.426  0.503
2013 Muller P, Ruckova E, Halada P, Coates PJ, Hrstka R, Lane DP, Vojtesek B. C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene. 32: 3101-10. PMID 22824801 DOI: 10.1038/Onc.2012.314  0.367
2013 Bernard H, Garmy-Susini B, Ainaoui N, Van Den Berghe L, Peurichard A, Javerzat S, Bikfalvi A, Lane DP, Bourdon JC, Prats AC. The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression. Oncogene. 32: 2150-60. PMID 22733133 DOI: 10.1038/Onc.2012.242  0.407
2013 Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, Coffill CR, Lane DP, Sansom OJ, Neilsen PM, Norman JC, et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene. 32: 1252-65. PMID 22580601 DOI: 10.1038/Onc.2012.148  0.45
2013 Horikawa I, Fujita K, Jenkins LM, Hiyoshi Y, Mondal AM, Vojtesek B, Lane DP, Appella E, Harris CC. Abstract PR08: Autophagic degradation of Δ133p53 during replicative cellular senescence: An isoform-specific protein degradation mechanism for p53 Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-Pr08  0.498
2012 Lane DP, Verma C. Mdm2 in evolution. Genes & Cancer. 3: 320-4. PMID 23150765 DOI: 10.1177/1947601912458285  0.417
2012 Zhou W, Quah ST, Verma CS, Liu Y, Lane DP, Brown CJ. Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects. Plos One. 7: e47235. PMID 23094039 DOI: 10.1371/Journal.Pone.0047235  0.335
2012 Joseph TL, Lane DP, Verma CS. Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations. Plos One. 7: e43985. PMID 22952838 DOI: 10.1371/Journal.Pone.0043985  0.302
2012 Funston G, Goh W, Wei SJ, Tng QS, Brown C, Jiah Tong L, Verma C, Lane D, Ghadessy F. Binding of Translationally Controlled Tumour Protein to the N-terminal domain of HDM2 is inhibited by nutlin-3. Plos One. 7: e42642. PMID 22912717 DOI: 10.1371/Journal.Pone.0042642  0.466
2012 Goh AM, Lane DP. How p53 wields the scales of fate: arrest or death? Transcription. 3: 240-4. PMID 22885979 DOI: 10.4161/trns.21297  0.373
2012 Coffill CR, Muller PA, Oh HK, Neo SP, Hogue KA, Cheok CF, Vousden KH, Lane DP, Blackstock WP, Gunaratne J. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. Embo Reports. 13: 638-44. PMID 22653443 DOI: 10.1038/Embor.2012.74  0.465
2012 Terrier O, Marcel V, Cartet G, Lane DP, Lina B, Rosa-Calatrava M, Bourdon JC. Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α. Journal of Virology. 86: 8452-60. PMID 22647703 DOI: 10.1128/Jvi.07143-11  0.39
2012 Dastidar SG, Lane DP, Verma CS. Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding. Cell Cycle (Georgetown, Tex.). 11: 2239-47. PMID 22617389 DOI: 10.4161/Cc.20333  0.394
2012 Camus S, Ménendez S, Fernandes K, Kua N, Liu G, Xirodimas DP, Lane DP, Bourdon JC. The p53 isoforms are differentially modified by Mdm2. Cell Cycle (Georgetown, Tex.). 11: 1646-55. PMID 22487680 DOI: 10.4161/Cc.20119  0.51
2012 Goh AM, Lim CY, Chiam PC, Li L, Mann MB, Mann KM, Menendez S, Lane DP. Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proceedings of the National Academy of Sciences of the United States of America. 109: 1685-90. PMID 22307631 DOI: 10.1073/Pnas.1114173109  0.482
2012 Marcel V, Petit I, Murray-Zmijewski F, Goullet de Rugy T, Fernandes K, Meuray V, Diot A, Lane DP, Aberdam D, Bourdon JC. Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity. Cell Death and Differentiation. 19: 816-26. PMID 22075982 DOI: 10.1038/Cdd.2011.152  0.519
2012 Lane DP, Cheok CF. p53 Pathway and Cancer Therapy Aacr Education Book. 2012: 171-176. DOI: 10.1158/Aacr.Edb-12-6400  0.371
2011 Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget. 2: 1203-17. PMID 22203497 DOI: 10.18632/Oncotarget.382  0.498
2011 Lane DP, Madhumalar A, Lee AP, Tay BH, Verma C, Brenner S, Venkatesh B. Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish. Cell Cycle (Georgetown, Tex.). 10: 4272-9. PMID 22107961 DOI: 10.4161/Cc.10.24.18567  0.403
2011 Lane DP, Brown CJ, Verma C, Cheok CF. New insights into p53 based therapy. Discovery Medicine. 12: 107-17. PMID 21878188  0.366
2011 Lew QJ, Tan CH, Gurumurthy M, Chu KL, Cheong N, Lane DP, Chao SH. NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds. Cell Cycle (Georgetown, Tex.). 10: 1978-87. PMID 21558800 DOI: 10.4161/Cc.10.12.15859  0.437
2011 Ménendez S, Goh AM, Camus S, Ng KW, Kua N, Badal V, Lane DP. MDM4 downregulates p53 transcriptional activity and response to stress during differentiation. Cell Cycle (Georgetown, Tex.). 10: 1100-8. PMID 21422812 DOI: 10.4161/Cc.10.7.15090  0.487
2011 Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, Lane DP, Thompson AM. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Research : Bcr. 13: R7. PMID 21251329 DOI: 10.1186/Bcr2811  0.38
2011 Dastidar SG, Raghunathan D, Nicholson J, Hupp TR, Lane DP, Verma CS. Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle (Georgetown, Tex.). 10: 82-9. PMID 21191186 DOI: 10.4161/Cc.10.1.14345  0.622
2011 Brown CJ, Cheok CF, Verma CS, Lane DP. Reactivation of p53: from peptides to small molecules. Trends in Pharmacological Sciences. 32: 53-62. PMID 21145600 DOI: 10.1016/J.Tips.2010.11.004  0.519
2011 Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. The Journal of Pathology. 223: 116-26. PMID 21125670 DOI: 10.1002/Path.2784  0.497
2011 Brown CJ, Lim JJ, Leonard T, Lim HC, Chia CS, Verma CS, Lane DP. Stabilizing the eIF4G1 α-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies. Journal of Molecular Biology. 405: 736-53. PMID 21094167 DOI: 10.1016/J.Jmb.2010.10.045  0.328
2011 Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nature Reviews. Clinical Oncology. 8: 25-37. PMID 20975744 DOI: 10.1038/Nrclinonc.2010.174  0.468
2011 Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP, Bourdon JC. p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death and Differentiation. 18: 248-58. PMID 20689555 DOI: 10.1038/Cdd.2010.91  0.481
2011 Lane DP, Brown C, Khoo KH, Goh A, Lin G, Liew HP, Verma C, Cheok CF. Abstract IA10: How the p53 pathway controls the response to chemotherapy Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-Ia10  0.489
2011 Mondal AM, Horikawa I, Pine SR, Fujita K, Vojtesek B, Bourdon J, Vera E, Lane DP, Blasco MA, Harris CC. Abstract B1: p53 isoforms, Δ133p53 and p53β, regulate aging-associated T lymphocyte senescence. Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-B1  0.33
2011 Liu Y, Lane DP, Verma CS. Systematic mutational analysis of an ubiquitin ligase (MDM2)-binding peptide: Computational studies Theoretical Chemistry Accounts. 130: 1145-1154. DOI: 10.1007/S00214-011-1049-Y  0.353
2010 Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 1: 639-50. PMID 21317459 DOI: 10.18632/Oncotarget.198  0.46
2010 Joseph TL, Lane D, Verma CS. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein. Cell Cycle (Georgetown, Tex.). 9: 4560-8. PMID 21088491 DOI: 10.4161/Cc.9.22.13816  0.392
2010 Fujita K, Horikawa I, Mondal AM, Jenkins LM, Appella E, Vojtesek B, Bourdon JC, Lane DP, Harris CC. Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nature Cell Biology. 12: 1205-12. PMID 21057505 DOI: 10.1038/Ncb2123  0.475
2010 Wang S, Griffiths G, Midgley CA, Barnett AL, Cooper M, Grabarek J, Ingram L, Jackson W, Kontopidis G, McClue SJ, McInnes C, McLachlan J, Meades C, Mezna M, Stuart I, ... ... Lane DP, et al. Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chemistry & Biology. 17: 1111-21. PMID 21035734 DOI: 10.1016/J.Chembiol.2010.07.016  0.348
2010 See HY, Lane DP. A novel unstructured scaffold based on 4EBP1 enables the functional display of a wide range of bioactive peptides. Journal of Molecular Biology. 404: 819-31. PMID 20932973 DOI: 10.1016/J.Jmb.2010.09.063  0.365
2010 Goh AM, Lane DP. SNPing Away at Cancer. Cancer Cell. 18: 201-2. PMID 20832747 DOI: 10.1016/J.Ccr.2010.08.016  0.328
2010 Goh W, Lane D, Ghadessy F. Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions. Cell Cycle. 9: 3030-3038. PMID 20714218 DOI: 10.4161/Cc.9.15.12436  0.459
2010 Guo L, Chua J, Vijayakumar D, Lee KC, Lim K, Eng H, Ghadessy F, Coomber D, Lane DP. Detection of the 113p53 protein isoform: a p53-induced protein that feeds back on the p53 pathway to modulate the p53 response in zebrafish. Cell Cycle (Georgetown, Tex.). 9: 1998-2007. PMID 20505327 DOI: 10.4161/Cc.9.10.11732  0.469
2010 Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harbor Perspectives in Biology. 2: a001222. PMID 20463003 DOI: 10.1101/Cshperspect.A001222  0.491
2010 Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harbor Perspectives in Biology. 2: a000893. PMID 20463001 DOI: 10.1101/Cshperspect.A000893  0.439
2010 Cheok CF, Kua N, Kaldis P, Lane DP. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death and Differentiation. 17: 1486-500. PMID 20203688 DOI: 10.1038/Cdd.2010.18  0.481
2010 Dey A, Lane DP, Verma CS. Modulating the p53 pathway. Seminars in Cancer Biology. 20: 3-9. PMID 20193765 DOI: 10.1016/J.Semcancer.2010.02.004  0.482
2010 Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle (Georgetown, Tex.). 9: 1167-81. PMID 20190571 DOI: 10.4161/Cc.9.6.11067  0.51
2010 Lane DP, Cheok CF, Brown CJ, Madhumalar A, Ghadessy FJ, Verma C. The Mdm2 and p53 genes are conserved in the Arachnids. Cell Cycle (Georgetown, Tex.). 9: 748-54. PMID 20160485 DOI: 10.4161/Cc.9.4.10616  0.487
2010 Mavinahalli JN, Madhumalar A, Beuerman RW, Lane DP, Verma C. Differences in the transactivation domains of p53 family members: a computational study. Bmc Genomics. 11: S5. PMID 20158876 DOI: 10.1186/1471-2164-11-S1-S5  0.447
2010 Lane DP, Cheok CF, Brown C, Madhumalar A, Ghadessy FJ, Verma C. Mdm2 and p53 are highly conserved from placozoans to man. Cell Cycle (Georgetown, Tex.). 9: 540-7. PMID 20081368 DOI: 10.4161/Cc.9.3.10516  0.476
2010 Thompson AM, Lane DP. p53 transcriptional pathways in breast cancer: the good, the bad and the complex. The Journal of Pathology. 220: 401-3. PMID 20044802 DOI: 10.1002/Path.2674  0.437
2010 Brown CJ, Dastidar SG, See HY, Coomber DW, Ortiz-Lombardía M, Verma C, Lane DP. Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting. Journal of Molecular Biology. 395: 871-83. PMID 19895821 DOI: 10.1016/J.Jmb.2009.10.069  0.319
2010 Allende-Vega N, Sparks A, Lane DP, Saville MK. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene. 29: 432-41. PMID 19838211 DOI: 10.1038/Onc.2009.330  0.455
2010 Aoubala M, Murray-Zmijewski F, Khoury M, Perrier S, Fernandes K, Prats A, Lane D, Bourdon J. D133P53, directly transactivated by p53, prevents p53-mediated apoptosis without inhibiting p53-mediated cell cycle arrest Breast Cancer Research. 12. DOI: 10.1186/Bcr2505  0.511
2010 Horikawa I, Fujita K, Mondal AM, Vojtesek B, Bourdon J, Lane DP, Harris CC. Abstract 3199: p53 represses TRF2 through E3 ubiquitin ligase Siah-1: Feedback regulation in telomere-initiated damage signaling Cancer Research. 70: 3199-3199. DOI: 10.1158/1538-7445.Am10-3199  0.5
2010 Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe MA, Schetter AJ, Pine SR, Ji H, Vojtesek B, Bourdon J, Lane DP, Harris CC. Abstract 2915: p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence Cancer Research. 70: 2915-2915. DOI: 10.1158/1538-7445.Am10-2915  0.472
2009 Bourdon J, Diot A, Vojtesek B, Bray S, Jordan L, Lane DP, Thompson A. Scotin expression and survival in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e22006. PMID 27963176 DOI: 10.1200/Jco.2009.27.15_Suppl.E22006  0.356
2009 Dastidar SG, Lane DP, Verma CS. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100. Bmc Bioinformatics. 10: S6. PMID 19958516 DOI: 10.1186/1471-2105-10-S15-S6  0.495
2009 Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nature Reviews. Cancer. 9: 862-73. PMID 19935675 DOI: 10.1038/Nrc2763  0.493
2009 Wan KF, Wang S, Brown CJ, Yu VC, Entzeroth M, Lane DP, Lee MA. Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL. Cell Cycle (Georgetown, Tex.). 8: 3943-52. PMID 19901550 DOI: 10.4161/Cc.8.23.10114  0.33
2009 Madhumalar A, Lee HJ, Brown CJ, Lane D, Verma C. Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle (Georgetown, Tex.). 8: 2828-36. PMID 19713735 DOI: 10.4161/Cc.8.17.9516  0.423
2009 Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, Ji H, Vojtesek B, Bourdon JC, Lane DP, Harris CC. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nature Cell Biology. 11: 1135-42. PMID 19701195 DOI: 10.1038/Ncb1928  0.449
2009 Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle (Georgetown, Tex.). 8: 2810-8. PMID 19657224 DOI: 10.4161/Cc.8.17.9503  0.45
2009 Lau J, Lew QJ, Diribarne G, Michels AA, Dey A, Bensaude O, Lane DP, Chao SH. Ubiquitination of HEXIM1 by HDM2. Cell Cycle (Georgetown, Tex.). 8: 2247-54. PMID 19617712 DOI: 10.4161/Cc.8.14.9015  0.491
2009 Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, Ha NC, Lane DP, Song J. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. The Embo Journal. 28: 2100-13. PMID 19536131 DOI: 10.1038/Emboj.2009.164  0.5
2009 Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP, Peng J. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes & Development. 23: 278-90. PMID 19204115 DOI: 10.1101/Gad.1761609  0.507
2009 Madhumalar A, Jun LH, Lane DP, Verma CS. Dimerization of the core domain of the p53 family: a computational study. Cell Cycle (Georgetown, Tex.). 8: 137-48. PMID 19106606 DOI: 10.4161/Cc.8.1.7530  0.449
2009 Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. The Journal of Biological Chemistry. 284: 5030-41. PMID 19098288 DOI: 10.1074/Jbc.M805871200  0.496
2009 Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. International Journal of Cancer. Journal International Du Cancer. 124: 465-72. PMID 19003963 DOI: 10.1002/Ijc.23938  0.381
2009 Dastidar SG, Madhumalar A, Fuentes G, Lane DP, Verma CS. Forces mediating protein–protein interactions: a computational study of p53 “approaching” MDM2 Theoretical Chemistry Accounts. 125: 621-635. DOI: 10.1007/S00214-009-0682-1  0.443
2008 Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nature Reviews. Drug Discovery. 7: 1031-40. PMID 19043452 DOI: 10.1038/Nrd2759  0.387
2008 Dey A, Wong E, Kua N, Teo HL, Tergaonkar V, Lane D. Hexamethylene Bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF-κB activity: Implications for cancer therapy Cell Cycle. 7: 3759-3767. PMID 19029824 DOI: 10.4161/Cc.7.23.7213  0.352
2008 Staples OD, Hollick JJ, Campbell J, Higgins M, McCarthy AR, Appleyard V, Murray KE, Baker L, Thompson A, Ronseaux S, Slawin AM, Lane DP, Westwood NJ, Lain S. Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle (Georgetown, Tex.). 7: 3417-27. PMID 18971638 DOI: 10.4161/Cc.7.21.6982  0.438
2008 Janssen CO, Lim S, Lo EP, Wan KF, Yu VC, Lee MA, Ng SB, Everett MJ, Buss AD, Lane DP, Boyce RS. Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl. Bioorganic & Medicinal Chemistry Letters. 18: 5771-3. PMID 18845435 DOI: 10.1016/J.Bmcl.2008.09.071  0.315
2008 Dastidar SG, Lane DP, Verma CS. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. Journal of the American Chemical Society. 130: 13514-5. PMID 18800837 DOI: 10.1021/Ja804289G  0.342
2008 Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, Thompson A, Mathers J, Holland SJ, Stark MJ, Pass G, ... ... Lane DP, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 13: 454-63. PMID 18455128 DOI: 10.1016/J.Ccr.2008.03.004  0.373
2008 Gurumurthy M, Tan CH, Ng R, Zeiger L, Lau J, Lee J, Dey A, Philp R, Li Q, Lim TM, Price DH, Lane DP, Chao SH. Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. Journal of Molecular Biology. 378: 302-17. PMID 18371977 DOI: 10.1016/J.Jmb.2008.02.055  0.402
2008 Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP, Hersey P. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1659-68. PMID 18310316 DOI: 10.1158/1078-0432.Ccr-07-1422  0.462
2008 Brown CJ, Srinivasan D, Jun LH, Coomber D, Verma CS, Lane DP. The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle (Georgetown, Tex.). 7: 608-10. PMID 18256546 DOI: 10.4161/Cc.7.5.5488  0.418
2008 Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene. 27: 3371-83. PMID 18223694 DOI: 10.1038/Sj.Onc.1211010  0.473
2008 Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. British Journal of Cancer. 98: 4-8. PMID 18182973 DOI: 10.1038/Sj.Bjc.6604098  0.508
2008 Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death and Differentiation. 15: 263-73. PMID 17975552 DOI: 10.1038/Sj.Cdd.4402257  0.341
2008 Lee KC, Goh WL, Xu M, Kua N, Lunny D, Wong JS, Coomber D, Vojtesek B, Lane EB, Lane DP. Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene. 27: 629-40. PMID 17684488 DOI: 10.1038/Sj.Onc.1210695  0.485
2008 Xirodimas DP, Lane DP. Targeting a nucleolar SUMO protease for degradation: A mechanism by which ARF induces SUMO conjugation Cell Cycle. 7: 3287-3291. DOI: 10.4161/Cc.7.21.7232  0.422
2008 Cheok CF, Lane DP. New developments in small molecules targeting p53 pathways in anticancer therapy Drug Development Research. 69: 289-296. DOI: 10.1002/Ddr.20261  0.473
2007 Badal V, Menendez S, Coomber D, Lane DP. Regulation of the p14ARF promoter by DNA methylation. Cell Cycle (Georgetown, Tex.). 7: 112-9. PMID 18196972 DOI: 10.4161/Cc.7.1.5137  0.478
2007 Zocchi L, Bourdon JC, Codispoti A, Knight R, Lane DP, Melino G, Terrinoni A. Scotin: A new p63 target gene expressed during epidermal differentiation. Biochemical and Biophysical Research Communications. 367: 271-6. PMID 18164684 DOI: 10.1016/J.Bbrc.2007.12.115  0.436
2007 Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Molecular Cancer Research : McR. 5: 1133-45. PMID 18025259 DOI: 10.1158/1541-7786.Mcr-07-0161  0.431
2007 Hui JL, Srinivasan D, Coomber D, Lane DP, Verma CS. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: A computational study Cell Cycle. 6: 2604-2611. PMID 17957142 DOI: 10.4161/Cc.6.21.4923  0.432
2007 Hui JL, Gek HC, Krishnan A, Lane DP, Verma CS. Substrate specificity of cyclins determined by electrostatics Cell Cycle. 6: 2219-2226. PMID 17890901 DOI: 10.4161/Cc.6.18.4706  0.436
2007 Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP. Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle (Georgetown, Tex.). 6: 2178-85. PMID 17786042 DOI: 10.4161/Cc.6.17.4643  0.481
2007 Dey A, Chao SH, Lane DP. HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle (Georgetown, Tex.). 6: 1856-63. PMID 17671421 DOI: 10.4161/Cc.6.15.4556  0.454
2007 Fen CX, Coomber DW, Lane DP, Ghadessy FJ. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization. Journal of Molecular Biology. 371: 1238-48. PMID 17610896 DOI: 10.1016/J.Jmb.2007.05.099  0.485
2007 Vousden KH, Lane DP. p53 in health and disease. Nature Reviews. Molecular Cell Biology. 8: 275-83. PMID 17380161 DOI: 10.1038/Nrm2147  0.431
2007 Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. The Embo Journal. 26: 976-86. PMID 17290220 DOI: 10.1038/Sj.Emboj.7601567  0.508
2007 Camus S, Menéndez S, Cheok CF, Stevenson LF, Laín S, Lane DP. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene. 26: 4059-70. PMID 17224909 DOI: 10.1038/Sj.Onc.1210188  0.422
2007 Lim YP, Lim TT, Chan YL, Song AC, Yeo BH, Vojtesek B, Coomber D, Rajagopal G, Lane D. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene. 26: 1517-21. PMID 16953220 DOI: 10.1038/Sj.Onc.1209952  0.464
2007 Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death and Differentiation. 13: 962-72. PMID 16601753 DOI: 10.1038/sj.cdd.4401914  0.421
2007 Lane D. The P53 Pathway Genome Informatics. 19: 194-194. DOI: 10.11234/Gi1990.19.194  0.513
2006 Lane DP. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harbor Symposia On Quantitative Biology. 70: 489-97. PMID 16869788 DOI: 10.1101/Sqb.2005.70.049  0.462
2006 Dudgeon C, Kek C, Demidov ON, Saito SI, Fernandes K, Diot A, Bourdon JC, Lane DP, Appella E, Fornace AJ, Bulavin DV. Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene Cancer Research. 66: 2928-2936. PMID 16540640 DOI: 10.1158/0008-5472.Can-05-2063  0.487
2005 Chen J, Ruan H, Ng SM, Gao C, Soo HM, Wu W, Zhang Z, Wen Z, Lane DP, Peng J. Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes & Development. 19: 2900-11. PMID 16322560 DOI: 10.1101/Gad.1366405  0.411
2005 Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. The Journal of Pathology. 207: 251-9. PMID 16161005 DOI: 10.1002/Path.1838  0.49
2005 Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes & Development. 19: 2122-37. PMID 16131611 DOI: 10.1101/Gad.1339905  0.495
2005 Steele RJ, Lane DP. P53 in cancer: a paradigm for modern management of cancer. The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland. 3: 197-205. PMID 16076005 DOI: 10.1016/S1479-666X(05)80041-1  0.345
2005 MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Research. 65: 5399-407. PMID 15958589 DOI: 10.1158/0008-5472.Can-05-0233  0.331
2005 Berkson RG, Hollick JJ, Westwood NJ, Woods JA, Lane DP, Lain S. Pilot screening programme for small molecule activators of p53. International Journal of Cancer. Journal International Du Cancer. 115: 701-10. PMID 15729694 DOI: 10.1002/Ijc.20968  0.45
2005 Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, Lane DP, Hubank M, Powell JE, Wei W, Taylor AM, Moss PA, Stankovic T. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood. 105: 4484-91. PMID 15692065 DOI: 10.1182/Blood-2004-07-2713  0.348
2005 Kontopidis G, Wu SY, Zheleva DI, Taylor P, McInnes C, Lane DP, Fischer PM, Walkinshaw MD. Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proceedings of the National Academy of Sciences of the United States of America. 102: 1871-6. PMID 15681588 DOI: 10.1073/Pnas.0406540102  0.431
2005 Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. British Journal of Cancer. 92: 434-44. PMID 15668707 DOI: 10.1038/Sj.Bjc.6602358  0.401
2005 Bates GJ, Nicol SM, Wilson BJ, Jacobs AMF, Bourdon JC, Wardrop J, Gregory DJ, Lane DP, Perkins ND, Fuller-Pace FV. The DEAD box protein p68: A novel transcriptional coactivator of the p53 tumour suppressor Embo Journal. 24: 543-553. PMID 15660129 DOI: 10.1038/Sj.Emboj.7600550  0.505
2005 Lane DP. Worrying about p53. Current Biology : Cb. 2: 581-3. PMID 15336029 DOI: 10.1016/0960-9822(92)90154-3  0.463
2004 Karlsson GB, Jensen A, Stevenson LF, Woods YL, Lane DP, Sørensen MS. Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level. British Journal of Cancer. 91: 1488-94. PMID 15381928 DOI: 10.1038/Sj.Bjc.6602143  0.384
2004 Woods YL, Xirodimas DP, Prescott AR, Sparks A, Lane DP, Saville MK. p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase. The Journal of Biological Chemistry. 279: 50157-66. PMID 15355988 DOI: 10.1074/Jbc.M405414200  0.513
2004 Ljungman M, Lane DP. Transcription - guarding the genome by sensing DNA damage. Nature Reviews. Cancer. 4: 727-37. PMID 15343279 DOI: 10.1038/Nrc1435  0.305
2004 Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC, Woods YL, Lane DP. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. The Journal of Biological Chemistry. 279: 42169-81. PMID 15280377 DOI: 10.1074/Jbc.M403362200  0.458
2004 Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell. 118: 83-97. PMID 15242646 DOI: 10.1016/J.Cell.2004.06.016  0.465
2004 Fischer PM, Lane DP. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends in Pharmacological Sciences. 25: 343-6. PMID 15219971 DOI: 10.1016/J.Tips.2004.04.011  0.489
2004 Lane D. Curing cancer with p53. The New England Journal of Medicine. 350: 2711-2. PMID 15215489 DOI: 10.1056/Nejmcibr041288  0.461
2004 Lane D. Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy. Carcinogenesis. 25: 1077-81. PMID 15205365 DOI: 10.1093/Carcin/Bgh186  0.439
2004 McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chemistry & Biology. 11: 525-34. PMID 15123247 DOI: 10.1016/J.Chembiol.2004.03.022  0.303
2004 Lane DP, Fischer PM. Turning the key on p53. Nature. 427: 789-90. PMID 14985740 DOI: 10.1038/427789A  0.446
2004 Woods YL, Lane DP. Exploiting the p53 pathway for cancer diagnosis and therapy. The Hematology Journal : the Official Journal of the European Haematology Association. 4: 233-47. PMID 12872148 DOI: 10.1038/Sj.Thj.6200260  0.37
2004 Lane D. Developing new treatments for breast cancer Breast Cancer Research. 6: 1-1. DOI: 10.1186/Bcr820  0.52
2004 Fischer PM, Glover DM, Lane DP. Targeting the cell cycle Drug Discovery Today: Therapeutic Strategies. 1: 417-423. DOI: 10.1016/J.Ddstr.2004.11.014  0.33
2003 Kontopidis G, Andrews MJ, McInnes C, Cowan A, Powers H, Innes L, Plater A, Griffiths G, Paterson D, Zheleva DI, Lane DP, Green S, Walkinshaw MD, Fischer PM. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (London, England : 1993). 11: 1537-46. PMID 14656438 DOI: 10.1016/J.Str.2003.11.006  0.375
2003 Lain S, Lane D. Improving cancer therapy by non-genotoxic activation of p53. European Journal of Cancer (Oxford, England : 1990). 39: 1053-60. PMID 12736103 DOI: 10.1016/S0959-8049(03)00063-7  0.489
2003 Bourdon JC, Laurenzi VD, Melino G, Lane D. p53: 25 years of research and more questions to answer Cell Death & Differentiation. 10: 397-399. PMID 12719714 DOI: 10.1038/Sj.Cdd.4401243  0.345
2003 Zheleva DI, Lane DP, Fischer PM. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. Mini Reviews in Medicinal Chemistry. 3: 257-70. PMID 12698949 DOI: 10.2174/1389557033488178  0.504
2003 Lane DP, Hupp TR. Drug discovery and p53. Drug Discovery Today. 8: 347-55. PMID 12681938 DOI: 10.1016/S1359-6446(03)02669-2  0.629
2003 McInnes C, Andrews MJ, Zheleva DI, Lane DP, Fischer PM. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Current Medicinal Chemistry. Anti-Cancer Agents. 3: 57-69. PMID 12678915 DOI: 10.2174/1568011033353506  0.39
2003 Menéndez S, Higgins M, Berkson RG, Edling C, Lane DP, Laín S. Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. British Journal of Cancer. 88: 636-43. PMID 12592381 DOI: 10.1038/Sj.Bjc.6600752  0.308
2003 Camus S, Higgins M, Lane DP, Lain S. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. Febs Letters. 536: 220-4. PMID 12586367 DOI: 10.1016/S0014-5793(03)00054-1  0.448
2003 Menéndez S, Khan Z, Coomber DW, Lane DP, Higgins M, Koufali MM, Lain S. Oligomerization of the human ARF tumor suppressor and its response to oxidative stress. The Journal of Biological Chemistry. 278: 18720-9. PMID 12582152 DOI: 10.1074/Jbc.M211007200  0.378
2003 Zheleva DI, McInnes C, Gavine AL, Zhelev NZ, Fischer PM, Lane DP. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. The Journal of Peptide Research : Official Journal of the American Peptide Society. 60: 257-70. PMID 12383116 DOI: 10.1034/J.1399-3011.2002.21014.X  0.461
2002 Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. Febs Letters. 528: 207-11. PMID 12297306 DOI: 10.1016/S0014-5793(02)03310-0  0.362
2002 Shreeram S, Sparks A, Lane DP, Blow JJ. Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene. 21: 6624-32. PMID 12242660 DOI: 10.1038/Sj.Onc.1205910  0.376
2002 Blattner C, Hay T, Meek DW, Lane DP. Hypophosphorylation of Mdm2 augments p53 stability. Molecular and Cellular Biology. 22: 6170-82. PMID 12167711 DOI: 10.1128/Mcb.22.17.6170-6182.2002  0.48
2002 Bourdon J-, Renzing J, Robertson PL, Fernandes KN, Lane DP. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane Journal of Cell Biology. 158: 235-246. PMID 12135983 DOI: 10.1083/Jcb.200203006  0.456
2002 Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends in Molecular Medicine. 8: S38-42. PMID 11927286 DOI: 10.1016/S1471-4914(02)02309-2  0.512
2002 Fischer PM, Krausz E, Lane DP. Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjugate Chemistry. 12: 825-41. PMID 11716670 DOI: 10.1021/Bc0155115  0.304
2001 Coates PJ, Lorimore SA, Rigat BA, Lane DP, Wright EG. Induction of endogenous beta-galactosidase by ionizing radiation complicates the analysis of p53-LacZ transgenic mice. Oncogene. 20: 7096-7. PMID 11704833 DOI: 10.1038/Sj.Onc.1204904  0.311
2001 Liu WL, Midgley C, Stephen C, Saville M, Lane DP. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. Journal of Molecular Biology. 313: 711-31. PMID 11697899 DOI: 10.1006/Jmbi.2001.5082  0.516
2001 Lane D. How cells choose to die Nature. 414: 25-27. PMID 11689924 DOI: 10.1038/35102132  0.498
2001 Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK, Jochemsen AG. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. Embo Reports. 2: 1029-34. PMID 11606419 DOI: 10.1093/Embo-Reports/Kve227  0.51
2001 Xirodimas DP, Stephen CW, Lane DP. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Experimental Cell Research. 270: 66-77. PMID 11597128 DOI: 10.1006/Excr.2001.5314  0.499
2001 Xirodimas D, Saville MK, Edling C, Lane DP, Laín S. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene. 20: 4972-83. PMID 11526482 DOI: 10.1038/Sj.Onc.1204656  0.49
2001 Lipinski K, Djeha A, Krausz E, Lane D, Searle P, Mountain A, Wrighton C. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53. Gene Therapy. 8: 274-281. PMID 11313801 DOI: 10.1038/Sj.Gt.3301403  0.426
2001 Schumacher U, Adam E, Feldhaus S, Katoh M, Lane DP. Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice. Cancer Letters. 166: 215-21. PMID 11311495 DOI: 10.1016/S0304-3835(01)00395-0  0.436
2001 Mattock H, Jares P, Zheleva DI, Lane DP, Warbrick E, Blow JJ. Use of peptides from p21 (Waf1/Cip1) to investigate PCNA function in Xenopus egg extracts. Experimental Cell Research. 265: 242-51. PMID 11302689 DOI: 10.1006/Excr.2001.5181  0.358
2001 Mattock H, Lane DP, Warbrick E. Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Experimental Cell Research. 265: 234-41. PMID 11302688 DOI: 10.1006/Excr.2001.5160  0.49
2000 Paramio JM, Segrelles C, Laín S, Gómez-Casero E, Lane DP, Lane EB, Jorcano JL. p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes. Molecular Carcinogenesis. 29: 251-62. PMID 11170263 DOI: 10.1002/1098-2744(200012)29:4<251::Aid-Mc1007>3.0.Co;2-O  0.504
2000 Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 408: 307-10. PMID 11099028 DOI: 10.1038/35042675  0.411
2000 Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Molecular and Cellular Biology. 20: 8458-67. PMID 11046142 DOI: 10.1128/Mcb.20.22.8458-8467.2000  0.499
2000 Fischer PM, Lane DP. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Current Medicinal Chemistry. 7: 1213-45. PMID 11032968 DOI: 10.2174/0929867003374048  0.408
2000 Ottaggio L, Bozzo S, Moro F, Sparks A, Campomenosi P, Miele M, Bonatti S, Fronza G, Lane DP, Abbondandolo A. Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification. Carcinogenesis. 21: 1631-8. PMID 10964093 DOI: 10.1093/Carcin/21.9.1631  0.46
2000 Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proceedings of the National Academy of Sciences of the United States of America. 97: 8501-6. PMID 10900010 DOI: 10.1073/Pnas.97.15.8501  0.436
2000 Herbert TP, Fåhraeus R, Prescott A, Lane DP, Proud CG. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Current Biology : Cb. 10: 793-6. PMID 10898981 DOI: 10.1016/S0960-9822(00)00567-4  0.356
2000 Zheleva DI, Zhelev NZ, Fischer PM, Duff SV, Warbrick E, Blake DG, Lane DP. A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics. Biochemistry. 39: 7388-97. PMID 10858286 DOI: 10.1021/Bi992498R  0.478
2000 Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 19: 2312-23. PMID 10822382 DOI: 10.1038/Sj.Onc.1203593  0.503
2000 Burch LR, Midgley CA, Currie RA, Lane DP, Hupp TR. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. Febs Letters. 472: 93-8. PMID 10781812 DOI: 10.1016/S0014-5793(00)01427-7  0.487
2000 Lane D, Midgley C, Sparks A, Blattner C, Binden C, Laine S. Drug discovery in the p53 pathway Breast Cancer Research. 2. DOI: 10.1186/Bcr137  0.364
2000 HUPP TR, LANE DP, BALL KL. Strategies for manipulating the p53 pathway in the treatment of human cancer Biochemical Journal. 352: 1-17. DOI: 10.1042/Bj3520001  0.644
1999 Smart P, Lane EB, Lane DP, Midgley C, Vojtesek B, Laín S. Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene. 18: 7378-86. PMID 10602494 DOI: 10.1038/Sj.Onc.1203260  0.479
1999 Cohen PA, Hupp TR, Lane DP, Daniels DA. Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein. Febs Letters. 463: 179-84. PMID 10601663 DOI: 10.1016/S0014-5793(99)01603-8  0.634
1999 Laín S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Experimental Cell Research. 253: 315-24. PMID 10585254 DOI: 10.1006/Excr.1999.4672  0.441
1999 Kendall MD, Lane DP, Schumacher U. Immunohistochemical and ultrastructural evidence for myelopoiesis in the scid/scid mouse thymus Histochemical Journal. 31: 651-660. PMID 10576414 DOI: 10.1023/A:1003895519669  0.314
1999 Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. The Embo Journal. 18: 6455-61. PMID 10562557 DOI: 10.1093/Emboj/18.22.6455  0.51
1999 Xirodimas DP, Lane DP. Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. The Journal of Biological Chemistry. 274: 28042-9. PMID 10488156 DOI: 10.1074/Jbc.274.39.28042  0.475
1999 Fåhraeus R, Fischer P, Krausz E, Lane DP. New approaches to cancer therapies. The Journal of Pathology. 187: 138-46. PMID 10341714 DOI: 10.1002/(Sici)1096-9896(199901)187:1<138::Aid-Path252>3.0.Co;2-M  0.338
1999 Laín S, Midgley C, Sparks A, Lane EB, Lane DP. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Experimental Cell Research. 248: 457-72. PMID 10222137 DOI: 10.1006/Excr.1999.4433  0.514
1999 Blattner C, Sparks A, Lane D. Transcription Factor E2F-1 Is Upregulated in Response to DNA Damage in a Manner Analogous to That of p53 Molecular and Cellular Biology. 19: 3704-3713. PMID 10207094 DOI: 10.1128/Mcb.19.5.3704  0.545
1999 Fåhraeus R, Lane DP. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. The Embo Journal. 18: 2106-18. PMID 10205165 DOI: 10.1093/Emboj/18.8.2106  0.461
1999 Böttger V, Böttger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, Lane DP. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene. 18: 189-99. PMID 9926934 DOI: 10.1038/Sj.Onc.1202281  0.528
1999 Lane D, C M, Sparks A, Blattner C, Bindon C, Lain S. Regulation of p53 stability. The role of Mdm2 and nuclear export Biochemical Society Transactions. 27: A64-A64. DOI: 10.1042/Bst027A064A  0.411
1998 Nikolova PV, Henckel J, Lane DP, Fersht AR. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proceedings of the National Academy of Sciences of the United States of America. 95: 14675-80. PMID 9843948 DOI: 10.1073/Pnas.95.25.14675  0.42
1998 Cohen PA, Mani JC, Lane DP. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene. 17: 2445-56. PMID 9824155 DOI: 10.1038/Sj.Onc.1202190  0.426
1998 Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. The British Journal of Surgery. 85: 1460-7. PMID 9823903 DOI: 10.1046/J.1365-2168.1998.00910.X  0.444
1998 Warbrick E, Heatherington W, Lane DP, Glover DM. PCNA binding proteins in Drosophila melanogaster: The analysis of a conserved PCNA binding domain Nucleic Acids Research. 26: 3925-3932. PMID 9705499 DOI: 10.1093/Nar/26.17.3925  0.417
1998 Fåhraeus R, Laín S, Ball KL, Lane DP. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene. 16: 587-96. PMID 9482104 DOI: 10.1038/Sj.Onc.1201580  0.434
1998 Hansen S, Lane DP, Midgley CA. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability. Journal of Molecular Biology. 275: 575-88. PMID 9466932 DOI: 10.1006/Jmbi.1997.1507  0.43
1998 Böttger A, Böttger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Current Biology : Cb. 7: 860-9. PMID 9382809 DOI: 10.1016/S0960-9822(06)00374-5  0.501
1997 Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR. Thermodynamic stability of wild-type and mutant p53 core domain. Proceedings of the National Academy of Sciences of the United States of America. 94: 14338-42. PMID 9405613 DOI: 10.1073/Pnas.94.26.14338  0.348
1997 Lane DP, Hall PA. MDM2--arbiter of p53's destruction. Trends in Biochemical Sciences. 22: 372-4. PMID 9357310 DOI: 10.1016/S0968-0004(97)01119-5  0.421
1997 Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15: 1179-89. PMID 9294611 DOI: 10.1038/Sj.Onc.1201459  0.52
1997 Mundt M, Hupp T, Fritsche M, Merkle C, Hansen S, Lane D, Groner B. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential Oncogene. 15: 237-244. PMID 9244359 DOI: 10.1038/Sj.Onc.1201174  0.643
1997 Fourie AM, Hupp TR, Lane DP, Sang BC, Barbosa MS, Sambrook JF, Gething MJ. HSP70 binding sites in the tumor suppressor protein p53. The Journal of Biological Chemistry. 272: 19471-9. PMID 9235949 DOI: 10.1074/jbc.272.31.19471  0.622
1997 Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM, Lane DP. Molecular characterization of the hdm2-p53 interaction. Journal of Molecular Biology. 269: 744-56. PMID 9223638 DOI: 10.1006/Jmbi.1997.1078  0.505
1997 Midgley CA, White S, Howitt R, Save V, Dunlop MG, Hall PA, Lane DP, Wyllie AH, Bubb VJ. APC expression in normal human tissues. The Journal of Pathology. 181: 426-33. PMID 9196441 DOI: 10.1002/(Sici)1096-9896(199704)181:4<426::Aid-Path768>3.0.Co;2-T  0.335
1997 Warbrick E, Lane DP, Glover DM, Cox LS. Homologous regions of Fen1 and p21(Cip1) compete for binding to the same site on PCNA: A potential mechanism to co-ordinate DNA replication and repair Oncogene. 14: 2313-2321. PMID 9178907 DOI: 10.1038/Sj.Onc.1201072  0.357
1997 Hall PA, Lane DP. Tumor suppressors: a developing role for p53? Current Biology : Cb. 7: R144-7. PMID 9162475 DOI: 10.1016/S0960-9822(97)70074-5  0.399
1997 Bliss TM, Lane DP. Ku selectively transfers between DNA molecules with homologous ends. The Journal of Biological Chemistry. 272: 5765-73. PMID 9038190 DOI: 10.1074/Jbc.272.9.5765  0.317
1997 Ball KL, Lain S, Fâhraeus R, Smythe C, Lane DP. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Current Biology : Cb. 7: 71-80. PMID 8999999 DOI: 10.1016/S0960-9822(06)00029-7  0.474
1996 Hansen S, Midgley CA, Lane DP, Freeman BC, Morimoto RI, Hupp TR. Modification of two distinct COOH-terminal domains is required for murine p53 activation by bacterial Hsp70. The Journal of Biological Chemistry. 271: 30922-8. PMID 8940078 DOI: 10.1074/Jbc.271.48.30922  0.667
1996 Daniels DA, Lane DP. Phage Peptide Libraries Methods. 9: 494-507. PMID 8812705 DOI: 10.1006/Meth.1996.0057  0.319
1996 Fåhraeus R, Paramio JM, Ball KL, Laín S, Lane DP. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Current Biology : Cb. 6: 84-91. PMID 8805225 DOI: 10.1016/S0960-9822(02)00425-6  0.42
1996 Picksley SM, Spicer JF, Barnes DM, Lane DP. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. Acta Oncologica (Stockholm, Sweden). 35: 429-34. PMID 8695156 DOI: 10.3109/02841869609109917  0.485
1996 Ball KL, Lane DP. Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1. European Journal of Biochemistry. 237: 854-61. PMID 8647134 DOI: 10.1111/J.1432-1033.1996.0854P.X  0.398
1996 Hansen S, Hupp TR, Lane DP. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. The Journal of Biological Chemistry. 271: 3917-24. PMID 8632013 DOI: 10.1074/Jbc.271.7.3917  0.678
1996 Kernohan NM, Hupp TR, Lane DP. Modification of an N-terminal regulatory domain of T antigen restores p53-T antigen complex formation in the absence of an essential metal ion cofactor. The Journal of Biological Chemistry. 271: 4954-60. PMID 8617769 DOI: 10.1074/Jbc.271.9.4954  0.601
1996 Lane D, Hupp T, Warbrick E, Picksley S, Sparks A, Farheus R, Paramio J, Ball K, Lain S, Glover D, Hall P. Regulating and replacing suppressor gene function with small synthetic molecules; design of an active synthetic suppressor protein Biochemical Society Transactions. 24: 592S-592S. DOI: 10.1042/Bst024592Sa  0.563
1996 Dewar DA, Spraggon C, Midgeley C, Lane D, Prescott A, Spruce BA. NUCLEAR PROENKEPHALIN INDUCES CELL DEATH IN A P53 DOSE-DEPENDENT MANNER Biochemical Society Transactions. 24: 571S-571S. DOI: 10.1042/Bst024571Sb  0.363
1995 Lane DP. p53 and human cancers. British Medical Bulletin. 50: 582-99. PMID 7987642 DOI: 10.1093/Oxfordjournals.Bmb.A072911  0.531
1995 Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP, Santibáñez-Koref MF. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. British Journal of Cancer. 70: 1176-81. PMID 7981072 DOI: 10.1038/bjc.1994.468  0.335
1995 Picksley SM, Lane DP. p53 and Rb: their cellular roles. Current Opinion in Cell Biology. 6: 853-8. PMID 7880533 DOI: 10.1016/0955-0674(94)90056-6  0.425
1995 Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers. Current Biology : Cb. 4: 865-75. PMID 7850419 DOI: 10.1016/S0960-9822(00)00195-0  0.686
1995 Lane DP, Lu X, Hupp T, Hall PA. The role of the p53 protein in the apoptotic response. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 345: 277-80. PMID 7846126 DOI: 10.1098/Rstb.1994.0106  0.681
1995 Warbrick E, Lane DP, Glover DM, Cox LS. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen Current Biology. 5: 275-282. PMID 7780738 DOI: 10.1016/S0960-9822(95)00058-3  0.41
1995 Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentani RR, Lane DP. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. British Journal of Cancer. 71: 1253-6. PMID 7779720 DOI: 10.1038/Bjc.1995.242  0.44
1995 Hann BC, Lane DP. The dominating effect of mutant p53. Nature Genetics. 9: 221-2. PMID 7773278 DOI: 10.1038/Ng0395-221  0.431
1995 Lane DP, Midgley CA, Hupp TR, Lu X, Vojtesek B, Picksley SM. On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 347: 83-7. PMID 7746859 DOI: 10.1098/Rstb.1995.0013  0.659
1995 Hupp TR, Lane DP. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. The Journal of Biological Chemistry. 270: 18165-74. PMID 7629129 DOI: 10.1074/Jbc.270.30.18165  0.661
1995 Hupp TR, Lane DP. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symposia On Quantitative Biology. 59: 195-206. PMID 7587070 DOI: 10.1101/SQB.1994.059.01.024  0.63
1995 Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53 Cell. 83: 237-245. PMID 7585941 DOI: 10.1016/0092-8674(95)90165-5  0.676
1995 Cox LS, Lane DP. Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage Bioessays. 17: 501-508. PMID 7575491 DOI: 10.1002/Bies.950170606  0.463
1995 Stephen CW, Helminen P, Lane DP. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. Journal of Molecular Biology. 248: 58-78. PMID 7537340 DOI: 10.1006/Jmbi.1995.0202  0.388
1995 Cox L, Hupp T, Midgley C, Lane D. A direct effect of activated human p53 on nuclear DNA replication. The Embo Journal. 14: 2099-2105. DOI: 10.1002/J.1460-2075.1995.Tb07201.X  0.638
1994 Lane DP. The regulation of p53 function: Steiner Award Lecture. International Journal of Cancer. 57: 623-7. PMID 8194867 DOI: 10.1002/Ijc.2910570502  0.433
1994 Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. British Journal of Cancer. 69: 943-6. PMID 8180028 DOI: 10.1038/Bjc.1994.182  0.432
1994 Ogden GR, Cowpe JG, Chisholm DM, Lane DP. p53 immunostaining as a marker for oral cancer in diagnostic cytopathology--preliminary report. Cytopathology : Official Journal of the British Society For Clinical Cytology. 5: 47-53. PMID 8173031 DOI: 10.1111/J.1365-2303.1994.Tb00127.X  0.421
1994 Lane DP. On the expression of the p53 protein in human cancer. Molecular Biology Reports. 19: 23-9. PMID 8170465 DOI: 10.1007/Bf00987319  0.447
1994 Petty RD, Cree IA, Sutherland LA, Hunter EM, Lane DP, Preece PE, Andreotti PE. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biochemical and Biophysical Research Communications. 199: 264-70. PMID 8123022 DOI: 10.1006/bbrc.1994.1223  0.397
1994 Dowell SP, Lane DP, Hall PA. The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology : Official Journal of the British Society For Clinical Cytology. 5: 76-81. PMID 8038426 DOI: 10.1111/J.1365-2303.1994.Tb00530.X  0.477
1994 Daniels DA, Lane DP. The characterisation of p53 binding phage isolated from phage peptide display libraries. Journal of Molecular Biology. 243: 639-52. PMID 7966288 DOI: 10.1016/0022-2836(94)90038-8  0.51
1994 Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! The Journal of Pathology. 172: 1-4. PMID 7931821 DOI: 10.1002/Path.1711720103  0.426
1994 Hall PA, Coates PJ, Goodlad RA, Hart IR, lane DP. Proliferating cell nuclear antigen expression in non-cycling cells may be induced by growth factors in vivo. British Journal of Cancer. 70: 244-7. PMID 7914422 DOI: 10.1038/Bjc.1994.287  0.32
1994 Picksley SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 15: 689-90. PMID 7506024 DOI: 10.1002/Bies.950151008  0.423
1994 Picksley SM, Hupp TR, Lu X, Midgley CA, Vojtesek B, Lane DP. Regulation of p53 protein expression in human cancer Cancer Genetics and Cytogenetics. 77: 153. DOI: 10.1016/0165-4608(94)90250-X  0.627
1994 Nissim A, Hoogenboom H, Tomlinson I, Flynn G, Midgley C, Lane D, Winter G. Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. The Embo Journal. 13: 692-698. DOI: 10.1002/J.1460-2075.1994.Tb06308.X  0.382
1993 Lane DP, Midgley C, Hupp T. Tumour suppressor genes and molecular chaperones. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 339: 369-72; discussion 3. PMID 8493291 DOI: 10.1098/Rstb.1993.0036  0.652
1993 Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, Kovarik J, Millis RR, Lane DP, Barnes DM. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. European Journal of Cancer (Oxford, England : 1990). 881-6. PMID 8484983 DOI: 10.1016/S0959-8049(05)80431-9  0.408
1993 Lane DP. Cancer. A death in the life of p53. Nature. 362: 786-7. PMID 8479514 DOI: 10.1038/362786A0  0.348
1993 Ro YS, Cooper PN, Lee JA, Quinn AG, Harrison D, Lane D, Horne CH, Rees JL, Angus B. p53 protein expression in benign and malignant skin tumours. The British Journal of Dermatology. 128: 237-41. PMID 8471506 DOI: 10.1111/J.1365-2133.1993.Tb00164.X  0.308
1993 Grand RJA, Lecane PS, Roberts S, Grant ML, Lane DP, Young LS, Dawson CW, Gallimore PH. Overexpression of wild-type p53 and c-myc in human fetal cells transformed with adenovirus early region 1 Virology. 193: 579-591. PMID 8460477 DOI: 10.1006/Viro.1993.1166  0.414
1993 Ogden GR, Lane DP, Chisholm DM. p53 expression in dyskeratosis congenita: a marker for oral premalignancy? Journal of Clinical Pathology. 46: 169-70. PMID 8459038 DOI: 10.1136/Jcp.46.2.169  0.409
1993 Dowell S, Derias N, Wilson PO, Lane DP, Hall PA. Expression of p53 in reactive mesothelium. Histopathology. 22: 96-7. PMID 8436353 DOI: 10.1111/J.1365-2559.1993.Tb00086.X  0.426
1993 Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris AL, Mason DY. Immunohistochemical detection of p53 and bcl‐2 proteins in non‐Hodgkin's lymphoma Histopathology. 22: 39-44. PMID 8436340 DOI: 10.1111/J.1365-2559.1993.Tb00067.X  0.4
1993 Bártek J, Bártková J, Lukás J, Stasková Z, Vojtĕsek B, Lane DP. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. The Journal of Pathology. 169: 27-34. PMID 8433213 DOI: 10.1002/Path.1711690106  0.496
1993 Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Research. 21: 3167-74. PMID 8341590 DOI: 10.1093/Nar/21.14.3167  0.654
1993 Doussis IA, Pezzella F, Lane DP, Gatter KC, Mason DY. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. American Journal of Clinical Pathology. 99: 663-7. PMID 8322700 DOI: 10.1093/Ajcp/99.6.663  0.388
1993 Joypaul BV, Vojtesek B, Newman EL, Hopwood D, Grant A, Lane DP, Cuschieri A. Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. Histopathology. 23: 465-70. PMID 8314221 DOI: 10.1111/J.1365-2559.1993.Tb00496.X  0.418
1993 Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell. 75: 765-78. PMID 8242748 DOI: 10.1016/0092-8674(93)90496-D  0.401
1993 Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. The Journal of Pathology. 170: 279-83. PMID 8133401 DOI: 10.1002/Path.1711700310  0.361
1993 Filipe MI, Mendes R, Lane DP, Morris RW. Assessment of proliferating cell nuclear antigen expression in precursor stages of gastric carcinoma using the PC10 antibody in PCNA Histopathology. 22: 349-354. PMID 8099897 DOI: 10.1111/J.1365-2559.1993.Tb00134.X  0.313
1993 Vojtĕsek B, Fisher CJ, Barnes DM, Lane DP. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. British Journal of Cancer. 67: 1254-8. PMID 7685617 DOI: 10.1038/Bjc.1993.234  0.451
1993 Soini Y, Kamel D, Nuorva K, Lane DP, Vähäkangas K, Pääkkö P. Low p53 protein expression in salivary gland tumours compared with lung carcinomas. Virchows Archiv. a, Pathological Anatomy and Histopathology. 421: 415-20. PMID 1333678 DOI: 10.1007/Bf01606914  0.365
1993 Soini Y, Vähäkangas K, Nuorva K, Kamel D, Lane DP, Pääkkö P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. The Journal of Pathology. 168: 29-33. PMID 1333524 DOI: 10.1002/Path.1711680106  0.429
1993 Kovarik J, Vojtesek B, Lauerova L, Barnes D, Lane D. Comparisons and significance of immunohistochemistry and cytosol p53 assay in matched breast cancer samples European Journal of Cancer. 29: S195. DOI: 10.1016/0959-8049(93)91712-T  0.332
1993 Barnes DM, Fisher CJ, Rasbridge SA, MacGeoch C, Lane DP. The p53 protein detected by immunohistochemical staining is not always mutant Journal of Cellular Biochemistry. 53: 248-248. DOI: 10.1002/Jcb.240531147  0.429
1993 Fuller-Pace F, Nicol S, Reid A, Lane D. DbpA: a DEAD box protein specifically activated by 23s rRNA. The Embo Journal. 12: 3619-3626. DOI: 10.1002/J.1460-2075.1993.Tb06035.X  0.314
1992 Walker RA, Dearing SJ, Lane DP, Varley JM. Expression of p53 protein in infiltrating and in-situ breast carcinomas. The Journal of Pathology. 165: 203-11. PMID 1684809 DOI: 10.1002/Path.1711650303  0.401
1992 Lu X, Park SH, Thompson TC, Lane DP. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell. 70: 153-61. PMID 1623518 DOI: 10.1016/0092-8674(92)90541-J  0.34
1992 Lane DP. Cancer. p53, guardian of the genome. Nature. 358: 15-6. PMID 1614522 DOI: 10.1038/358015A0  0.354
1992 Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. International Journal of Cancer. 50: 859-62. PMID 1555884 DOI: 10.1002/IJC.2910500604  0.303
1992 Bennett WP, Hollstein MC, Hsu IC, Sidransky D, Lane DP, Vogelstein B, Harris CC. Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest. 101: 19S-20S. PMID 1541189 DOI: 10.1378/Chest.101.3_Supplement.19S  0.369
1992 Coverley D, Kenny MK, Lane DP, Wood RD. A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair Nucleic Acids Research. 20: 3873-3880. PMID 1508673 DOI: 10.1093/Nar/20.15.3873  0.317
1992 Ogden GR, Chisholm DM, Kiddie RA, Lane DP. p53 protein in odontogenic cysts: increased expression in some odontogenic keratocysts. Journal of Clinical Pathology. 45: 1007-10. PMID 1452774 DOI: 10.1136/Jcp.45.11.1007  0.44
1992 Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell. 71: 875-86. PMID 1423635 DOI: 10.1016/0092-8674(92)90562-Q  0.667
1992 Soini Y, Pääkkö P, Nuorva K, Kamel D, Lane DP, Vähäkangas K. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Archiv. a, Pathological Anatomy and Histopathology. 421: 223-8. PMID 1413488 DOI: 10.1007/Bf01611179  0.395
1992 Kafiri G, Thomas DM, Shepherd NA, Krausz T, Lane DP, Hall PA. p53 expression is common in malignant mesothelioma. Histopathology. 21: 331-4. PMID 1398535 DOI: 10.1111/J.1365-2559.1992.Tb00403.X  0.483
1992 Ogden GR, Kiddie RA, Lunny DP, Lane DP. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. The Journal of Pathology. 166: 389-94. PMID 1381431 DOI: 10.1002/Path.1711660411  0.406
1992 Vojtĕsek B, Bártek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. Journal of Immunological Methods. 151: 237-44. PMID 1378473 DOI: 10.1016/0022-1759(92)90122-A  0.482
1992 Stephen CW, Lane DP. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. Journal of Molecular Biology. 225: 577-83. PMID 1376364 DOI: 10.1016/0022-2836(92)90386-X  0.41
1992 Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. The Journal of Urology. 147: 496-9. PMID 1370701 DOI: 10.1016/S0022-5347(17)37287-7  0.337
1992 Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology. 103: 1769-76. PMID 1360434 DOI: 10.1016/0016-5085(92)91433-5  0.454
1992 Pignatelli M, Stamp GW, Kafiri G, Lane D, Bodmer WF. Over-expression of p53 nuclear oncoprotein in colorectal adenomas. International Journal of Cancer. Journal International Du Cancer. 50: 683-8. PMID 1347513 DOI: 10.1002/Ijc.2910500503  0.487
1992 Vahakangas KH, Metcalf RA, Welsh JA, Bennett WP, Harris CC, Samet JM, Lane DP. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners The Lancet. 339: 576-580. PMID 1347094 DOI: 10.1016/0140-6736(92)90866-2  0.346
1992 Ellison DW, Gatter KC, Steart PV, Lane DP, Weller RO. Expression of the p53 protein in a spectrum of astrocytic tumours. The Journal of Pathology. 168: 383-6. PMID 1336544 DOI: 10.1002/Path.1711680408  0.495
1992 Bártek J, Vojtĕsek B, Lane DP. Diversity of human p53 mutants revealed by complex formation to SV40 T antigen. European Journal of Cancer (Oxford, England : 1990). 101-7. PMID 1332735 DOI: 10.1016/0959-8049(93)90584-3  0.462
1992 McLaren R, Kuzu L, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung British Journal of Cancer. 66: 735-738. PMID 1329907 DOI: 10.1038/Bjc.1992.348  0.416
1992 Lane DP. Checkpoint policing by p53 Nature. 359: 486-487. DOI: 10.1038/359486B0  0.464
1992 Waseem N, Labib K, Nurse P, Lane D. Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. The Embo Journal. 11: 5111-5120. DOI: 10.1002/J.1460-2075.1992.Tb05618.X  0.351
1991 Gannon JV, Lane DP. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature. 349: 802-6. PMID 2000149 DOI: 10.1038/349802A0  0.417
1991 Iggo RD, Jamieson DJ, MacNeill SA, Southgate J, McPheat J, Lane DP. p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Molecular and Cellular Biology. 11: 1326-33. PMID 1996094 DOI: 10.1128/mcb.11.3.1326-1333.1991  0.34
1991 Coverley D, Kenny MK, Munn M, Rupp WD, Lane DP, Wood RD. Requirement for the replication protein SSB in human DMA excision repair Nature. 349: 538-541. PMID 1992355 DOI: 10.1038/349538A0  0.319
1991 Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Horne CH, Neal DE. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. British Journal of Cancer. 63: 967-70. PMID 1712624 DOI: 10.1038/Bjc.1991.211  0.385
1991 Woods AL, Hall PA, Shepherd NA, Hanby AM, Waseem NH, Lane DP, Levison DA. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis Histopathology. 19: 21-27. PMID 1680784 DOI: 10.1111/J.1365-2559.1991.Tb00890.X  0.321
1991 Wilcock D, Lane DP. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature. 349: 429-31. PMID 1671528 DOI: 10.1038/349429A0  0.349
1991 Bártková J, Bártek J, Lukás J, Vojtĕsek B, Stasková Z, Rejthar A, Kovarík J, Midgley CA, Lane DP. p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. International Journal of Cancer. 49: 196-202. PMID 1652567 DOI: 10.1002/Ijc.2910490209  0.444
1991 Wrede D, Tidy JA, Crook T, Lane D, Vousden KH. Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Molecular Carcinogenesis. 4: 171-175. PMID 1648361 DOI: 10.1002/Mc.2940040302  0.404
1990 Bártek J, Bártková J, Vojtĕsek B, Stasková Z, Rejthar A, Kovarík J, Lane DP. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. International Journal of Cancer. 46: 839-44. PMID 2228312 DOI: 10.1002/Ijc.2910460515  0.416
1990 Iggo R, Picksley S, Southgate J, McPheat J, Lane DP. Identification of a putative RNA helicase in E.coli. Nucleic Acids Research. 18: 5413-7. PMID 2216714 DOI: 10.1093/Nar/18.18.5413  0.335
1990 Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes & Development. 4: 1-8. PMID 2137806 DOI: 10.1101/Gad.4.1.1  0.441
1990 Iggo R, Bartek J, Lane D, Gatter K, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. The Lancet. 335: 675-679. PMID 1969059 DOI: 10.1016/0140-6736(90)90801-B  0.404
1990 Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 87: 7555-9. PMID 1699228 DOI: 10.1073/Pnas.87.19.7555  0.479
1990 Gannon J, Greaves R, Iggo R, Lane D. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. The Embo Journal. 9: 1595-1602. DOI: 10.1002/J.1460-2075.1990.Tb08279.X  0.507
1989 Iggo R, Gough A, Xu W, Lane DP, Spurr NK. Chromosome mapping of the human gene encoding the 68-kDa nuclear antigen (p68) by using the polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America. 86: 6211-4. PMID 2762324 DOI: 10.1073/Pnas.86.16.6211  0.358
1989 Iggo RD, Lane DP. Nuclear protein p68 is an RNA-dependent ATPase. The Embo Journal. 8: 1827-1831. DOI: 10.1002/J.1460-2075.1989.Tb03577.X  0.448
1988 Ford MJ, Anton IA, Lane DP. Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature. 332: 736-8. PMID 2451786 DOI: 10.1038/332736A0  0.412
1987 Gannon JV, Lane DP. p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature. 329: 456-8. PMID 3309672 DOI: 10.1038/329456A0  0.398
1987 Mole SE, Gannon JV, Ford MJ, Lane DP. Structure and function of SV40 large-T antigen. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 317: 455-69. PMID 2450379 DOI: 10.1098/Rstb.1987.0072  0.316
1986 Yewdell JW, Gannon JV, Lane DP. Monoclonal antibody analysis of p53 expression in normal and transformed cells. Journal of Virology. 59: 444-52. PMID 2426467 DOI: 10.1128/Jvi.59.2.444-452.1986  0.635
1986 Lane DP, Simanis V, Bartsch R, Yewdell J, Gannon J, Mole S. Cellular targets for SV40 large T-antigen. Proceedings of the Royal Society of London. Series B, Biological Sciences. 226: 25-42. PMID 2415984 DOI: 10.1098/Rspb.1985.0077  0.579
1985 Simanis V, Lane DP. An immunoaffinity purification procedure for SV40 large T antigen. Virology. 144: 88-100. PMID 2998049 DOI: 10.1016/0042-6822(85)90308-3  0.316
1985 Gorman CM, Rigby PWJ, Lane DP. Negative regulation of viral enhancers in undifferentiated embryonic stem cells Cell. 42: 519-526. PMID 2992802 DOI: 10.1016/0092-8674(85)90109-6  0.32
1984 Thomas R, Kaplan L, Reich N, Lane DP, Levine AJ. Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology. 131: 502-17. PMID 6318442 DOI: 10.1016/0042-6822(83)90516-0  0.456
1981 Lane DP, Hoeffler WK. SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature. 288: 167-70. PMID 6159551 DOI: 10.1038/288167A0  0.302
1981 Lane DP, Crawford LV. The complex between simian virus 40 T antigen and a specific host protein. Proceedings of the Royal Society of London. Series B, Biological Sciences. 210: 451-63. PMID 6109305 DOI: 10.1098/Rspb.1980.0146  0.322
1980 Hanahan D, Lane D, Lipsich L, Wigler M, Botchan M. Characteristics of an SV40-plasmid recombinant and its movement into and out of the genome of a murine cell. Cell. 21: 127-39. PMID 6250708 DOI: 10.1016/0092-8674(80)90120-8  0.309
Show low-probability matches.